drugs

National Institute of Health partners with 11 Biopharma companies for Cancer Research

National Institute of Health partners with 11 Biopharma companies for Cancer Research

The National Institutes of Health and 11 biopharmaceutical companies today launched the Partnership for Accelerating Cancer Therapies (PACT). This is a five-year-public-private research collaboration totaling $215 million as part of the Cancer Moons..

Halozyme Therapeutics Stock Up After Partnership with Roche

Halozyme Therapeutics Stock Up After Partnership with Roche

Halozyme Therapeutics, Inc. (NASDAQ: HALO) stock up more than 18% on Thursday after the biotechnology company announced that it has licensed its ENHANZE® drug-delivery technology to Roche for exclusive development of an undisclosed therapeutic t..

Eli Lilly to Cut 3,500 Jobs

Eli Lilly to Cut 3,500 Jobs

Drug making company Eli Lilly & Co. (NYSE:LLY)is planning on cutting 8.5% of their workforce and wants to close some facilities as the company is struggling with cost on some of their biggest products.The company has about 41,000 employees ..

Novartis Immunocellular Therapy Approved by FDA

Novartis Immunocellular Therapy Approved by FDA

Novartis AG (NYSE: NVS) announced Wednesday that the US Food and Drug Administration (FDA) has approved Kymriah (TM)(tisagenlecleucel) suspension for intravenous infusion, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment..

Esperion Therapeutics Presented Positive Top-Level Results for Phase 2 of Trials

Esperion Therapeutics Presented Positive Top-Level Results for Phase 2 of Trials

Esperion Therapeutics Inc (NASDAQ: ESPR) announced positive top-level results for Phase 2 of trials for triplet oral therapy with bempedoic acid, ezetimibe and atorvastatin.The trials, which lasted six weeks, have yilded positive data as the LDL-C l..

Valeant Pharmaceuticals Announced Q2 Earnings, Shares Jumped

Valeant Pharmaceuticals Announced Q2 Earnings, Shares Jumped

On Tuesday, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) announced its financial results for the second quarter. With earnings beating estimates, shares of the company increased 7.6% to $16.54 per share in morning trading on Tuesday after the announ..

AstraZeneca Shares fell on Disappointing Q2 Results and Cancer Study Results

AstraZeneca Shares fell on Disappointing Q2 Results and Cancer Study Results

AstraZeneca plc (NYSE: AZN) released a bevy of news today, including Q2 results, as well as study results for two drugs. AZN price has plummeted 15%.Following the loss of exclusivity for Crestor and Seroquel XR AstraZeneca had expected losses in the..